Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 5
![](https://www.dovepress.com/cr_data/cache/journal_image/38/cope/thumb_100_1000_100.jpg)
Pharmacogenomics and Personalized Medicine
ISSN: 1178-7066
- View all (649)
- Volume 17, 2024 (28)
- Volume 16, 2023 (97)
- Volume 15, 2022 (82)
- Volume 14, 2021 (155)
- Volume 13, 2020 (72)
- Volume 12, 2019 (34)
- Volume 11, 2018 (24)
- Volume 10, 2017 (31)
- Volume 9, 2016 (14)
- Volume 8, 2015 (16)
- Volume 7, 2014 (37)
- Volume 6, 2013 (15)
- Volume 5, 2012 (12)
- Volume 4, 2011 (10)
- Volume 3, 2010 (11)
- Volume 2, 2009 (9)
- Volume 1, 2008 (2)
Archive: Volume 5, 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients
Sirachainan E, Jaruhathai S, Trachu N, Panvichian R, Sirisinha T, Ativitavas T, Ratanatharathorn V, Chamnanphon M, Sukasem C
Pharmacogenomics and Personalized Medicine 2012, 5:149-153
Published Date: 17 October 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Drug targets and predictive biomarkers in the management of metastatic melanoma
Thumar J, Giesen E, Kluger HM
Pharmacogenomics and Personalized Medicine 2012, 5:139-148
Published Date: 28 September 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Boceprevir and personalized medicine in hepatitis C virus infection
Habersetzer F, Leboeuf C, Doffoël M, Baumert TF
Pharmacogenomics and Personalized Medicine 2012, 5:125-137
Published Date: 26 September 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Personalized medicine and treatment approaches in non-small-cell lung carcinoma
Vadakara J, Borghaei H
Pharmacogenomics and Personalized Medicine 2012, 5:113-123
Published Date: 25 September 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent
AL-Eitan LN, Jaradat SA, Su SY, Tay GK, Hulse GK
Pharmacogenomics and Personalized Medicine 2012, 5:99-111
Published Date: 7 September 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Role of pharmacogenomics in the treatment of tuberculosis: a review
Ramachandran G, Swaminathan S
Pharmacogenomics and Personalized Medicine 2012, 5:89-98
Published Date: 13 September 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Pharmacogenomic considerations in opioid analgesia
Vuilleumier PH, Stamer UM, Landau R
Pharmacogenomics and Personalized Medicine 2012, 5:73-87
Published Date: 23 August 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Individualized immunosuppression in transplant patients: potential role of pharmacogenetics
Abboudi H, MacPhee IA
Pharmacogenomics and Personalized Medicine 2012, 5:63-72
Published Date: 18 June 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics
Barratt DT, Coller JK, Hallinan R, Byrne A, White JM, Foster DJR, Somogyi AA
Pharmacogenomics and Personalized Medicine 2012, 5:53-62
Published Date: 18 April 2012
![Noteworthy comment: In this manuscript Williams and Morgan discuss and review the genetic and pharmacogenetics aspects of pre-eclampsia and address the pharmacogenomics of anti-platelet agents, alpha and beta blockers, calcium channel blockers and magnesium sulphate in relation to the treatment and prevention of pre-eclampsia.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The role of genetics in pre-eclampsia and potential pharmacogenomic interventions
Williams PJ, Morgan L
Pharmacogenomics and Personalized Medicine 2012, 5:37-51
Published Date: 20 January 2012
![Noteworthy comment: In this article, Dr Kenna and colleagues review the 5-HT transporter (5-HTTLPR) polymorphism alleles (LA/LG/S) and their associations with many psychiatric disorders.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy
Kenna GA, Roder-Hanna N, Leggio L, Zywiak WH, Clifford J, Edwards S, Kenna JA, Shoaff J, Swift RM
Pharmacogenomics and Personalized Medicine 2012, 5:19-35
Published Date: 13 January 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Individualization of antiretroviral therapy
Pavlos R, Phillips EJ
Pharmacogenomics and Personalized Medicine 2012, 5:1-17
Published Date: 29 December 2011